Document registry — page 38
Every document the Institute has published, 1,631 in total, with its identifier, type, certainty rating and review date.
Documents
-
Phase 1 ascending dose, phase 1 study of Liraglutide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low08 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low08 Aug 2023 -
Observational, phase 3 study of SS-31 (elamipretide) in mitochondrial disease over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low08 Aug 2023 -
Observational, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low07 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of AOD-9604 in obesity randomising 536 participants over 12 weeks. Primary result: No separation from…
05 Aug 2023 -
Randomised crossover, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Aug 2023 -
Phase 1 ascending dose, phase 1 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low03 Aug 2023 -
Diagnostic accuracy, phase 3 study of GHRP-2 in gh axis over single test. Primary result: Approved in Japan as a diagnostic stimulation agent. The Institute records that…
Moderate02 Aug 2023 -
Observational, phase 3 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low02 Aug 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low01 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ipamorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary…
Very low01 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of Danuglipron in obesity randomising 605 participants over 32 weeks. Primary result: Dose-dependent weight…
31 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of Ipamorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary…
Very low30 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity and prediabetes over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low28 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low28 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low27 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low27 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low27 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low26 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low26 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Larazotide acetate in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low25 Jul 2023 -
Randomised, open-label, active-controlled, phase 3 study of Exenatide in type 2 diabetes randomising 295 participants over 30 weeks. Primary result: Superior glycaemic…
High24 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Hexarelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low24 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low23 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Hexarelin in lean-mass preservation over as stated in the parent protocol. The Institute holds no reported…
Very low23 Jul 2023 -
Single-arm open-label, phase 1 study of Ipamorelin in gh axis over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low22 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Danuglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low20 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and chronic kidney disease and type 2 diabetes over as stated in the parent…
Very low19 Jul 2023 -
Randomised crossover, phase 1 study of Larazotide acetate in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low19 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low18 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in prediabetes and obesity randomising 2,254 participants over 160 weeks. Primary result…
Moderate17 Jul 2023 -
Randomised crossover, phase 1 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low17 Jul 2023 -
Observational, phase 3 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low16 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low15 Jul 2023 -
Sustained elevation of arterial pressure above accepted diagnostic thresholds, considered here as a weight-responsive outcome rather than a primary treatment indication.
13 Jul 2023 -
Observational, phase 2 study of SS-31 (elamipretide) in hfpef over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low13 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Cagrilintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low13 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The…
Very low13 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low10 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low10 Jul 2023
page 38 of 41